A leading Geman generics manufacturer Stada that it is in-licensing a biosimilar of Forteo
A leading Geman generics manufacturer Stada announced on October 13, 2014 that it is in-licensing a biosimilar of Forteo (teriparatide) from Richter-Helm BioTec. It will launch the product in Europe in 2019 after the patent on Eli Lilly’s original Forteo expires in December 2018. Teriparatide is a recombinant form of a human parathyroid hormone used to treat post-menopausal osteoporosis in women as well as primary osteoporosis and osteoporosis due to hypogonadism in men. Worldwide sales of Forteo reached 1.245 bn USD in 2013. Stada currently has 4 biosimilars in its portfolio (epoetin zeta, filgrastim, rituximab, trastuzumab), one of which has already been launched in Europe (Silapo, epoetin zeta).
Sources: Generics and Biosimilars Initiative (GaBI), EvaluatePharma®, Vidal